TECENTRIQ Adverse Reactions Profile in OAK

Adverse reactions (ARs) occurring in ≥10% of TECENTRIQ patients 1

*Graded per National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0.
Includes fatigue and asthenia.
Includes cough and exertional cough.
§Includes musculoskeletal pain, musculoskeletal stiffness, musculoskeletal chest pain, and myalgia.
Includes rash, erythematous rash, generalized rash, maculopapular rash, papular rash, pustular rash, and pemphigoid.

  • The most common ARs (≥20%) were fatigue (43.5%), decreased appetite (23.5%), dyspnea (22%), and cough (26.4%)
  • ARs led to discontinuation of TECENTRIQ in 8% of patients and treatment interruption in 25% of patients
  • 1.6% of patients experienced fatal ARs; these included pneumonia, sepsis, septic shock, dyspnea, pulmonary hemorrhage, sudden death, myocardial ischemia, or renal failure
  • Serious ARs occurred in 33.5% of patients. The most frequent (>1%) were pneumonia, sepsis, dyspnea, pleural effusion, pulmonary embolism, pyrexia, and respiratory tract infection

Laboratory abnormalities worsening from baseline occurring in ≥20% of TECENTRIQ patients 1*

ALT=alanine aminotransferase; AST=aspartate aminotransferase; q3w=every 3 weeks.
*Each test incidence is based on the number of patients who had both baseline and at least 1 on-study laboratory measurement available: TECENTRIQ (range: 546-585) and docetaxel (range: 532-560).